[EXEL] Exelixis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.41 Change: 0.47 (3.15%)
Ext. hours: 15.31 Change: -0.1 (-0.65%)

chart EXEL

Refresh chart

Strongest Trends Summary For EXEL

EXEL is in the medium-term down -13% in 2 months and down -35% below S&P in 1 year. In the long-term up 330% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 43.07% Sales Growth - Q/Q27.68% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-80.97% ROE156.1% ROI-102.16%
Current Ratio2.13 Quick Ratio2.09 Long Term Debt/Equity5.49 Debt Ratio-0.4
Gross Margin91.55% Operating Margin-615.77% Net Profit Margin-774.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-220 K Cash From Investing Activities49.9 M Cash From Operating Activities-45.09 M Gross Profit8.62 M
Net Profit-35.17 M Operating Profit-22.76 M Total Assets282.93 M Total Current Assets125.04 M
Total Current Liabilities58.68 M Total Debt368.43 M Total Liabilities429.69 M Total Revenue9.39 M
Technical Data
High 52 week24.76 Low 52 week13.65 Last close16.79 Last change2.5%
RSI23.17 Average true range0.64 Beta1.52 Volume4.05 M
Simple moving average 20 days-5.57% Simple moving average 50 days-12.22% Simple moving average 200 days-20.29%
Performance Data
Performance Week1.63% Performance Month-13.01% Performance Quart-22.66% Performance Half-26.52%
Performance Year3.39% Performance Year-to-date-14.64% Volatility daily1.91% Volatility weekly4.26%
Volatility monthly8.74% Volatility yearly30.26% Relative Volume263.48% Average Volume2.6 M
New High New Low

News

2019-11-12 16:05:00 | Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

2019-11-12 08:02:00 | Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® cabozantinib Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

2019-11-07 20:01:00 | Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

2019-11-04 22:59:26 | Edited Transcript of EXEL earnings conference call or presentation 30-Oct-19 9:00pm GMT

2019-10-31 11:45:03 | Exelixis EXEL Q3 Earnings Beat on Strong Cabometyx Sales

2019-10-30 18:45:10 | Exelixis EXEL Q3 Earnings and Revenues Beat Estimates

2019-10-30 16:05:00 | Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update

2019-10-30 08:00:35 | Is There An Opportunity With Exelixis, Inc.'s NASDAQ:EXEL 31% Undervaluation?

2019-10-29 10:40:02 | Exelixis EXEL to Report Q3 Earnings: What's in the Cards?

2019-10-25 10:15:01 | Is Exelixis, Inc. EXEL Going To Burn These Hedge Funds ?

2019-10-23 10:33:02 | Earnings Preview: Exelixis EXEL Q3 Earnings Expected to Decline

2019-10-16 16:05:00 | Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019

2019-10-14 12:08:25 | 7 Under-The-Radar Growth Stocks That Could Benefit New Investors

2019-10-07 11:58:19 | What Kind Of Shareholders Own Exelixis, Inc. NASDAQ:EXEL?

2019-10-07 09:54:01 | Calithera CALA Completes Enrollment in Mid-Stage RCC Study

2019-10-01 11:45:03 | Seattle Genetics Up on Positive Data From Bladder Cancer Study

2019-09-25 16:05:00 | Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

2019-09-23 10:27:02 | Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC

2019-09-20 17:48:23 | 3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices

2019-09-16 08:20:59 | Have Insiders Been Selling Exelixis, Inc. NASDAQ:EXEL Shares?

2019-09-13 09:36:01 | Renal Cell Carcinoma Space in Focus: Some Key Developments

2019-09-04 10:17:57 | Biotech vet George Scangos steers new company toward nine-figure IPO

2019-09-03 16:05:00 | Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

2019-08-26 08:04:48 | These Fundamentals Make Exelixis, Inc. NASDAQ:EXEL Truly Worth Looking At

2019-08-20 23:15:06 | Exelixis Inc EXEL EVP and General Counsel Jeffrey Hessekiel Sold $1.6 million of Shares

2019-08-20 10:09:02 | Exelixis EXEL Stock Up 15.2% YTD on Strong Cabometyx Sales

2019-08-16 21:15:03 | Exelixis Inc EXEL President and CEO Michael Morrissey Sold $704,654 of Shares

2019-08-05 10:00:00 | Exelixis Hits Blockbuster Status

2019-08-05 07:49:54 | Is Exelixis, Inc. NASDAQ:EXEL A High Quality Stock To Own?

2019-08-03 06:04:19 | Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT

2019-08-02 23:15:22 | Exelixis Inc EXEL President and CEO Michael Morrissey Sold $709,560 of Shares

2019-08-01 10:58:56 | Exelixis Stock Rises on Revenue Beat

2019-08-01 10:50:02 | Exelixis EXEL Q2 Earnings & Sales Beat, Cabometyx Shines

2019-08-01 07:18:16 | The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

2019-07-31 23:24:58 | Exelixis Inc EXEL Q2 2019 Earnings Call Transcript

2019-07-31 19:15:11 | Exelixis EXEL Q2 Earnings and Revenues Beat Estimates

2019-07-31 16:06:00 | Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update

2019-07-31 16:05:00 | Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

2019-07-31 07:06:00 | The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

2019-07-26 15:17:07 | Exelixis EXEL to Report Q2 Earnings: What's in the Cards?

2019-07-26 09:18:00 | 3 Cancer Treatment Stocks to Buy Right Now

2019-07-24 14:45:36 | 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar

2019-07-24 10:32:02 | Exelixis EXEL Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

2019-07-22 10:10:02 | Can Exelixis EXEL Keep the Earnings Surprise Streak Alive?

2019-07-19 23:15:04 | Exelixis Inc EXEL President and CEO Michael Morrissey Sold $741,988 of Shares

2019-07-18 11:45:03 | Exelixis NASDAQ:EXEL Shareholders Have Enjoyed A Whopping 474% Share Price Gain

2019-07-18 09:30:01 | EXEL or ILMN: Which Is the Better Value Stock Right Now?

2019-07-17 16:05:00 | Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019

2019-07-17 10:06:02 | Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

2019-07-17 09:20:01 | New Strong Buy Stocks for July 17th